Resources from the same session
512MO - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Presenter: Yan Yu
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast
513MO - Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis
Presenter: Byoung Chul Cho
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast
514MO - Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2
Presenter: Chee Khoon Lee
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session 2: Thoracic cancer
Resources:
Webcast
LBA9 - Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Hong Jian
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast
515MO - Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
Presenter: Hidehito Horinouchi
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast
516MO - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Presenter: Mariana Brandão
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA9, 515MO and 516MO
Presenter: Junko Tanizaki
Session: Mini oral session 2: Thoracic cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session 2: Thoracic cancer
Resources:
Webcast
490MO - Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431
Presenter: Koichi Goto
Session: Mini oral session 2: Thoracic cancer
Resources:
Abstract
Slides
Webcast